State Street Corp Purchases 70,008 Shares of Accuray Incorporated (NASDAQ:ARAY)

State Street Corp lifted its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 3.8% during the third quarter, Holdings Channel.com reports. The firm owned 1,894,287 shares of the medical equipment provider’s stock after buying an additional 70,008 shares during the quarter. State Street Corp’s holdings in Accuray were worth $3,410,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. raised its stake in Accuray by 143.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 384,944 shares of the medical equipment provider’s stock worth $693,000 after purchasing an additional 226,602 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Accuray by 1,650.6% in the third quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider’s stock valued at $263,000 after buying an additional 138,022 shares in the last quarter. FMR LLC raised its position in shares of Accuray by 27.2% in the third quarter. FMR LLC now owns 582,591 shares of the medical equipment provider’s stock valued at $1,049,000 after buying an additional 124,459 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Accuray in the third quarter valued at approximately $231,000. Finally, Foundry Partners LLC raised its position in shares of Accuray by 51.3% in the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after buying an additional 741,900 shares in the last quarter. 64.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Stock Down 2.2 %

NASDAQ ARAY opened at $1.79 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. Accuray Incorporated has a 1-year low of $1.40 and a 1-year high of $2.99. The company has a 50 day moving average of $1.91 and a 200-day moving average of $1.89. The company has a market cap of $180.01 million, a price-to-earnings ratio of -10.53 and a beta of 1.44.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The business had revenue of $101.55 million during the quarter, compared to the consensus estimate of $98.10 million. During the same period in the previous year, the business earned ($0.03) earnings per share. On average, equities research analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.